UroGen Pharma Ltd (Symbol: URGN) shares are currently trading at $37.94, surpassing the average analyst 12-month target price of $36.88. This shift prompts analysts to either downgrade their valuations or adjust their target prices accordingly. The current data shows variations in target prices among eight analysts, with one as low as $18.00 and another as high as $45.00, resulting in a standard deviation of $8.72.
As of now, analysts maintain a strong buy rating for UroGen Pharma, with 7 strong buy ratings and 2 hold ratings recorded. The average rating remains at 1.44 on a scale where 1 signifies strong buy and 5 indicates strong sell, consistent for the last three months.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
